DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Novo - 1 CDR132L - 1 Liselotte Sabroe - 1 Eli Lilly - 1 amycretin - 1 Martin Holst Lange - 1 Lange - 1
Top related locs:
Bagsvaerd Copenhagen Denmark Danish Novo London Saudi Mar
Top related orgs:
Novo Nordisk - 2 Denmark's - 1 Nordisk - 1 Cardior Pharmaceuticals - 1 AFP - 1 Getty - 1 Tesla - 1 Microsoft Corp MSFT - 1

Search resuls for: "Bagsvaerd"


5 mentions found


☆ Novo Nordisk strikes deal worth up to $1.1 billion to expand cardio business
  + stars: | 2024-03-25 | by ( ) www.cnbc.com   time to read: +1 min
A view of the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Denmark's Novo Nordisk said on Monday it had agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.1 billion) to strengthen its cardiovascular pipeline. The deal is in line with Novo's aim to expand its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments. The Danish company has rocketed to become one of the world's most valuable companies on the back of its hugely popular weight-loss treatment Wegovy. The deal includes Cardior's lead compound CDR132L, currently in intermediate Phase II clinical trials for the treatment of heart failure, Novo said.
Persons: Novo, CDR132L Organizations: Novo Nordisk, Denmark's, Nordisk, Cardior Pharmaceuticals Locations: Bagsvaerd, Copenhagen, Denmark, Danish, Novo
☆ Novo Nordisk market cap surpasses Tesla on new obesity pill trial data
  + stars: | 2024-03-08 | by ( Karen Gilchrist | ) www.cnbc.com   time to read: +2 min
Liselotte Sabroe | AFP | Getty ImagesWegovy obesity drug maker Novo Nordisk surpassed Tesla in market value, after fresh early trial data showed positive results for its new experimental weight loss pill. Novo Nordisk is now the 12th most valuable company in the world, with a market cap of $604 billion — ahead of Tesla's $569 billion, according to FactSet data. 8The uptick of Thursday extends a months-long rally for Novo Nordisk, as excitement grows around weight loss drugs and their potential wider applications. The early amycretin data marks a fresh milestone for Novo Nordisk, potentially offering a more effective and less intrusive alternative to its already widely successful injection-based Wegovy and Ozempic drugs. Wegovy showed weight loss of 6% in a 12-week trial, while Ozempic is a diabetes treatment.
Persons: Liselotte Sabroe, Eli Lilly, amycretin, Martin Holst Lange, Lange Organizations: AFP, Getty, Novo Nordisk, Tesla, Microsoft Corp MSFT, Apple Inc, AAPL, NVIDIA Corp NVDA Technology, Saudi Aramco, SA Energy, Inc, AMZN Consumer, GOOGL, Berkshire Hathaway BRK.B, Company LLY Healthcare, Broadcom Inc, AVGO Technology, Taiwan Semiconductor TSM, Novo Nordisk NVO, Finance, JPMorgan Chase JPM, Reuters Locations: Bagsvaerd, Copenhagen, Denmark, Danish, London, Saudi, Mar, Europe
☆ Novo Nordisk rivals see room to compete in $100 billion weight-loss drug market
  + stars: | 2023-05-04 | by ( Michael Erman | ) www.reuters.com   time to read: +6 min
The company has two oral GLP-1 drugs in mid-stage trials, and aims to choose one for a late-stage trial this year. He forecasts GLP-1s or similar drugs topping $100 billion in annual sales early in the 2030s, with Lilly's product accounting for more than $50 billion in sales. Smaller biotechs are also vying for a piece of the obesity market and hope large pharmaceutical companies will pay up for partnerships. "I don't know if it's $90 billion or $80 billion or $50 billion. The current GLP-1 drugs can cause nausea and vomiting.
☆ Drug maker Novo Nordisk invests $744 mln to expand Danish plant
  + stars: | 2022-11-22 | by ( ) www.reuters.com   time to read: +1 min
COPENHAGEN, Nov 22 (Reuters) - Danish drug maker Novo Nordisk (NOVOb.CO) said on Tuesday it plans to invest 5.4 billion Danish crowns ($744.09 million) to expand its existing facilities in Bagsvaerd, Denmark. Novo, the world's biggest producer of diabetes drugs, said the project is expected to be finalised in 2024 and create about 160 new jobs. "This investment in expanding our clinical API capacity in Bagsvaerd is an important step to ensure the continuous progress of our development pipeline," said senior vice president of Chemistry, Manufacturing and Control Development at Novo Nordisk, Jesper Boving. Novo Nordisk currently produces API at two facilities in Denmark and one in Clayton in the United States, a spokesperson told Reuters. ($1 = 7.2572 Danish crowns)Reporting by Rahat Sandhu and Stine Jacobsen, editing by Terje SolsvikOur Standards: The Thomson Reuters Trust Principles.
☆ Danish drug maker Novo Nordisk to invest $744 mln to expand facilities in Bagsvaerd
  + stars: | 2022-11-22 | by ( ) www.reuters.com   time to read: 1 min
Nov 22 (Reuters) - Danish drug maker Novo Nordisk (NOVOb.CO) announced on Tuesday it planned to invest 5.4 billion Danish crowns ($744.09 million) to expand its existing facilities in Bagsvaerd. The investment project is expected to be finalised in 2024 and create about 160 new jobs, the company said in a statement. ($1 = 7.2572 Danish crowns)Reporting by Rahat SandhuOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 5